JonesResearch analyst Justin Walsh downgraded Vor Bio (VOR) to Hold from Buy without a price target after the company announced it is exploring a range of strategic alternatives. The firm cites the wind down of Vor’s clinical and manufacturing operations and its 95% workforce reduction for the downgrade. The company’s planned and ongoing clinical trials as well as manufacturing operations have been suspended immediately, JonesResearch points out.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue